Here are five things to know about Nephron Pharmaceuticals, which makes respiratory medications, moved to South Carolina in 2011 and has invested in the state.

Health Canada Canadian drug regulator flagged problems at Nephron Pharmaceuticals’ “non-compliant” SC production facility in 2023 inspection ...

It says Nephron testing found cross-contamination in at least three lots of drug products. The FDA said, “You failed to adequately identify the root cause or scope of potentially impacted lots ...

Pioneering work in animals, in which glomeruli underwent direct in vivo measurement of the single-nephron GFR, showed that the single-nephron GFR increases to adapt to either a reduced number of ...

Nephron Pharmaceuticals' latest expansion project is the launch of a new business called Nephron Nitrile, a medical-grade nitrile glove manufacturing operation that will occupy 400,000 square feet in ...

Nephron, which moved to South Carolina in 2015, pumped $215.8 million into its facility in 2020 as it was experiencing explosive growth in its generic inhalation and suspension products.

Check your prescriptions: Fear of contaminated drugs has led the Department of Veterans Affairs to recall all medicines made by Nephron Pharmaceuticals. VA officials told 5 On Your Side they made ...

WEST COLUMBIA, S.C. — Local pharmaceutical corporation Nephron was recently flagged by the Canadian Health Agency for quality control and sterilization issues of their products. Canadian Health ...

WEST COLUMBIA, S.C. — U.S. drug regulators issued a report this week detailing issues at Nephron Pharmaceuticals. The inspection was conducted in February at the facility in West Columbia, which ...

WEST COLUMBIA, S.C. and NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Nephron Pharmaceuticals Corporation and Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an ...

The single-nephron glomerular filtration rate (GFR) is similar to total GFR assessed for all nephrons, according to results of a study published June 15 in the New England Journal of Medicine. "[T ...

This commentary discusses nephron protection in diabetic kidney disease and describes the way in which renin–angiotensin system inhibitors and the sodium–glucose cotransporter 2 inhibitor ...